Patients with hepatic impairment require careful Coreg CR dosage adjustments. Start with the lowest dose (3.125 mg once daily).
Monitor liver function tests (LFTs) regularly, especially at the beginning of therapy and with any dosage increase. Closely observe patients for signs of worsening hepatic dysfunction.
Dosage increases should be gradual and based on individual clinical response and tolerability, always keeping in mind the potential for increased risk of adverse events.
Consider reducing the Coreg CR dose if LFTs worsen significantly or if the patient experiences symptoms suggestive of hepatic dysfunction such as jaundice or fatigue.
Consult prescribing information for specific recommendations and always prioritize patient safety. Close monitoring is critical to ensure optimal therapy and minimize potential complications.
Remember to tailor treatment to the individual patient’s needs and regularly assess their response to medication.
